Protinádorová vakcína dendritickými buňkami naloženými Id proteinem u nemocných s mnohočetným myelomem, interní analýza bezpečnosti podání
| Title in English | Anticancer Id-protein Loaded Dendritic Cells Vaccine in Patiens with Mulptiple Myeloma, An Internal Safety Evaluation |
|---|---|
| Authors | |
| Year of publication | 2008 |
| Type | Article in Proceedings |
| Conference | Edukační sborník, XXXII. Brněnské onkologické dny a XXII. Konference pro nelékařské zdravotnické pracovníky |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | multiple myeloma; dendritic cells; immunotherapy; idiotype |
| Description | Patients (pts) with multiple myeloma not requiring systemic therapy were enrolled to the study. Pts received 6 doses of dendritic cells (DCs) loaded with autologous Id-protein every 4 weeks. Autologous mature DCs derived from peripherial blood monocytes were prepared in vitro and loaded with Id-protein. A clinical response was evaluated by measuring the monoclonal immunoglobulin levels. An immune response was monitored by flow cytometry, the production of interferon gamma (evaluated by Elispot) by myeloma-reactive T lymphocytes and a delayed type hypersensitivity test. Vaccination was well tolerated, no significant toxicities were observed in first 4 pts. A local reaction was observed in all pts and disappeared in 2-6 days. The immune response was noticed in 3 pts. No clinical response was observed. Vaccination with Id-protein loaded autologous DCs is a safe therapeutic strategy with no significant side effects. The trial will continue until a total number of 12 pts will be enrolled. |
| Related projects: |